The AFT Pharmaceuticals Ltd (ASX: AFP) share price is one to watch this morning.
Shares in the Kiwi-Australian pharmaceuticals group could be on the move after the company announced a new licensing agreement in the United States.
Why is the AFT Pharmaceuticals share price in focus?
This morning, the company announced the signing of an exclusive license and distribution agreement with Hikma Pharmaceuticals USA (“Hikma”). The new deal is to commercialise Maxigesic IV in the United States with the major pharmaceuticals supplier.
Maxigesic IV is an intravenous, opioid free, postoperative pain relief medicine developed by AFT. Today’s agreement represents the first out-license of the Maxigesic family of medicines in the US…
Health24 hours ago
I knew that was going to happen… The truth about premonitions – The Guardian
Science18 hours ago
Under watchful eye of NASA, teams prep for final Ariane 5 flight before Webb – Spaceflight Now – Spaceflight Now
Business11 hours ago
Twitter’s Dorsey warns of surging inflation after his platform ‘mistakenly’ censors GOP lawmaker’s video about . . . inflation – RT
Western News8 hours ago
Man arrested after allegedly illegally entering Queensland at Goondiwindi